Simple jQuery Dropdowns
Please use this identifier to cite or link to this item: http://repository.li.mahidol.ac.th/dspace/handle/123456789/58275
Title: Initial treatment response in ocular myasthenia gravis: A comparison between low and moderate doses of prednisolone
Authors: Thanatporn Threetong
Anuchit Poonyathalang
Pisit Preechawat
Panitha Jindahra
Tanyatuth Padungkiatsagul
Kavin Vanikieti
Faculty of Medicine, Ramathibodi Hospital, Mahidol University
Burapha University
Keywords: Medicine
Issue Date: 1-Jan-2020
Citation: Clinical Ophthalmology. Vol.14, (2020), 2051-2056
Abstract: © 2020 Threetong et al. Purpose: To evaluate the initial treatment response to low doses of prednisolone, compared with moderate doses, in ocular myasthenia gravis (OMG). Patients and Methods: A retrospective chart review of patients with adult-onset (age ≥15 years old) OMG, who were treated with prednisolone, was conducted. Subjects were divided into two groups according to their prednisolone dosing regimen. The low-dose group was defined as those with an average 12-week cumulative dose of prednisolone <0.435 mg/ kg/day and the moderate-dose group averaged 0.435–1.000 mg/kg/day. The primary outcome of interest was the comparison of clinical response to prednisolone at 12 weeks between the low-dose and moderate-dose groups. The secondary outcome was the difference in adverse events between treatment groups. Results: Of 34 subjects, 16 subjects (47.1%) were male. The mean age at onset was 44.0 ±18.1 years. The most common presenting ocular feature was ptosis with ophthalmoplegia (22 subjects, 64.7%), followed by isolated ptosis (nine subjects, 26.5%) and isolated ophthalmoplegia (three subjects, 8.8%). Half of the subjects were treated with low-dose prednisolone and the other half were treated with moderate-dose prednisolone. There were no substantial differences in baseline characteristics between treatment groups. After 12 weeks of treatment, nine of 17 subjects (52.9%) and 13 of 17 subjects (76.5%) in the low-and moderate-dose groups, respectively, were regarded as responsive to the prednisolone treatment (P=0.28). Adverse events were exclusively observed in the moderate-dose group. Conclusion: Treatment of OMG with an average 12-week cumulative dose of prednisolone <0.435 mg/kg/day (low dose) shows a comparable responsive outcome to 0.435–1.000 mg/ kg/day of prednisolone (moderate dose). Treating OMG with low-dose prednisolone can minimize prednisolone-related adverse events. However, a prospective randomized controlled trial with a larger study population is warranted in order to gain more insight into the proper dosage of prednisolone for OMG.
URI: http://repository.li.mahidol.ac.th/dspace/handle/123456789/58275
metadata.dc.identifier.url: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85088278426&origin=inward
ISSN: 11775483
11775467
Appears in Collections:Scopus 2020

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.